{"name":"Techpool Bio-Pharma Co., Ltd.","slug":"techpool-bio-pharma-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"kallikrein","genericName":"kallikrein","slug":"kallikrein","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"kallikrein","genericName":"kallikrein","slug":"kallikrein","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPWXd1YzVCN1oxZGFMUEdEcWpMUzYyZHJsa2h2QWVjanhjWmpLNjlXTnRMTGFHQVVtNVpkYUNyN1NaYy1KNVJDZXAyXzJWVDBTNVdZaldwNmV6LWFwd1FyYWVTOTdNUjljZnB4ZGg5VGV4bS1Ba1JMNmZPcmpQemtleGM2N2NBanNyX2Nka09lb1M1elpiQjhKbzE0SjhFRjNWZUJfd0xPZWZFd0x6bjN5QUtFZ29FQVF0dk5VT0VJQ2FxYWVoMlpWNHkwOXhGSXVINDBlbWdqc1pydkk?oc=5","date":"2026-04-05","type":"pipeline","source":"bastillepost.com","summary":"HK Media’s Jiangsu Tour: Aidea Pharmaceutical's HIV Drug Breakthrough Sets Sights on the World - bastillepost.com","headline":"HK Media’s Jiangsu Tour: Aidea Pharmaceutical's HIV Drug Breakthrough Sets Sights on the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1rM0wxbE1BUEk4c3lTMnBSREF3ZExGZ1ZISXp3X1BpMFBNMldhMWl6Z0lMQjF5amkyc0IyTmRmekxaU0w2cVIwdmx5UWw4NDJNZFRXeldyS2JISUQ1SVBnQVNZbDU0TTdGVHdLamxR?oc=5","date":"2024-07-18","type":"pipeline","source":"Allied Market Research","summary":"Urokinase Market Statistics, Segments Analysis| Forecast- 2033 - Allied Market Research","headline":"Urokinase Market Statistics, Segments Analysis| Forecast- 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQalRVVFRMUTRSTTVBMkktcUotdTh6M1c2SkxNLW1YTk5aUG1NYnE2NUpPNm9BWGxpc1RMc2k1elBUNU5zVW1XNVJURzA3VDhJYkpoSjVXMmtFa0FtRHBmS2RrZEl1NVVTaEQwNlZoY1dvSjB4T3RRSG1nN09SRUlxYzVYN2xwSjRtMkI4aG1R?oc=5","date":"2024-02-08","type":"pipeline","source":"Frontiers","summary":"Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases - Frontiers","headline":"Therapeutic Values of Human Urinary Kallidinogenase on Cerebrovascular Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQOXl2S2lRN3BSYlRXcFhIRzR2aXVYNV8zaHpHWG5JWnFQcFUzUnEzYUV4Nm5VajJuRjRUZzYxdHVXUjlMV3FxRlFUMW0xMVNzVkNDaDFWR2FpdGppU21CUkFrQmROcDZfTVpRUDlCRndiSnNpUFQ5b3JfNFNLX19pbXJpdkI?oc=5","date":"2020-10-01","type":"trial","source":"Clinical Trials Arena","summary":"Top ten pharma companies in 2020 - Clinical Trials Arena","headline":"Top ten pharma companies in 2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxObmEzbTJ4RjNJZXhxZWV2VFZyZ1laT1JGbzNXY0J2WnBqbzdocFdBU0JydExfZEg5Z1FpRVdDRmlWWmxoTHhrbU5UZTRaODBZdnNqdEUtNVR0Qm9OUS1qSXZLNTZubkxJQ0lfa1RoUXBqNFl2WVJDMlNQT2dnbXRjYjRpTi1HWU5ib013M0FnUEtCZw?oc=5","date":"2019-11-08","type":"pipeline","source":"openPR.com","summary":"Aprotinin Market to Witness Robust Expansion by 2024 - openPR.com","headline":"Aprotinin Market to Witness Robust Expansion by 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPeWRDaVlQa0xzcktiR3N2NkdER0pYLS13Mm45N2d1dFVMRjJVaV9iOFpQd21nRU9xZEw1a3lJRV9fV19haXJiSm9BLUxpcFV1R3Z3WWxqcUtYa1c5d2VPQjgyYTlBeVlBTzhSeDlYTDV0ODcxSFJaZFNKUzVHU3ItZ2hJa3FMTUlPalJwZTVIS0tnUVROV1BRS2VQRkVuZHJIMERHdl82c0VjZF9vSkx4Yk5NTkxyNmsyV3BQZ3hvVQ?oc=5","date":"2018-05-30","type":"pipeline","source":"Zacks Small Cap Research","summary":"DMA.V: What Does the Shanghai Pharma Acquisition Mean to DiaMedica? - Zacks Small Cap Research","headline":"DMA.V: What Does the Shanghai Pharma Acquisition Mean to DiaMedica?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}